RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Tumori Neuroendocrini Polmonari (Carcinoidi) e Gastro-Entero-Pancreatici (GEP): Caratterizzazione clinica, immunofenotipica e molecolare nella definizione della prognosi e dell'iter terapeutico.
• 2 - Avanzamenti nella diagnosi molecolare e nel trattamento dei tumori neuroendocrini
• 3 - Terapia sistemica primaria del carcinoma mammario in stadio iniziale: ricadute cliniche, biologiche e molecolari.
• 4 - Studio delle alterazioni biomolecolari e dei profili di espressione genica nel carcinoma colorettale e pancreatico: identificazione di possibili elementi prognostici e bersagli terapeutici nel sistema degli eicosanoidi e dei cannabinoidi.
• 5 - Genomica e proteomica dei gliomi cerebrali: un approccio bioinformatico
• 6 - Recettori per i fattori di crescita e loro vie di trasduzione come bersagli per terapie di associazione mirate in oncologia
• 7 - Valutazione della risposta tumorale con parametri biologici, immunologici e di imaging funzionale
• 8 - RUOLO DEGLI ORMONI IPOFISARI NELLE NEOPLASIE.
• 9 - Implicazioni diagnostico-terapeutiche delle nuove conoscenze cliniche e molecolari del carcinoma midollare della tiroide.
• 10 - Sviluppo di trattamenti sperimentali e clinici per il carcinoma pancreatico

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • ONCOLOGIA MEDICA
  • ANATOMIA PATOLOGICA
  • GASTROENTEROLOGIA
  • CHIRURGIA GENERALE

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]

Classificazione geografica

• Regione: Emilia Romagna

Bibliografia

1 Oberg K, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J, Haglund C, Knigge U, Vatn MH, Valimaki M. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms) - Part I - General overview. Acta Oncol 2004; 43:617-25.
2 Solcia E, Klöppel G, Sobin LH. Histological Typing of Endocrine Tumours 2nd Edition. Springer: Berlin; 2000.
3 Oberg K, Astrup L, Eriksson B, Falkmer SE, Falkmer UG, Gustafsen J, Haglund C, Knigge U, Vatn MH, Valimaki M. Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms) - Part II - Specific NE tumour types. Acta Oncol 2004; 43:626-36.
4 Blay JY, Le Cesne A, Alberti L, Ray-Coquart I. Targeted cancer therapies. Bull Cancer. 2005; 92(2):E13-8.
5 Williams ED, Sandler M: The classification of carcinoid tumours. Lancet 1963;1: 238-9.
6 Solcia E, Capella C, Fiocca R, Sessa F, LaRosa S, Rindi G: Disorders of the endocrine system; in Ming SC, Goldman H (eds): Pathology of the gastrointestinal tract. pp 295-322. Philadelphia: Williams and Wilkins, 1998.
7 Toliat MR, Berger W, Ropers HH, Neuhaus P, Wiedenmann B: Mutations in the MEN I gene in sporadic neuroendocrine tumours of gastroenteropancreatic system [letter]. Lancet 1997;350: 1223.
8 Görtz B, Roth J, Krahenmann A, de Krijger RR, Muletta-Feurer S, Rutimann K, Saremaslani P, Speel EJ, Heitz PU, Komminoth P: Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms. Am J Pathol 1999;154: 429-36.
9 Moore PS, Missiaglia E, Antonello D, Zamo A, Zamboni G, Corleto V, Falconi M, Scarpa A: Role of disease-causing genes in sporadic pancreatic endocrine tumors: MEN1 and VHL. Genes Chromosomes Cancer 2001;32: 177-81.
10 D'Adda T, Pizzi S, Azzoni C, Bottarelli L., Crafa P., Pasquali C., Davoli C., Corleto V. D., Delle Fave G., Bordi C. Different patterns of 11q allelic losses in digestive endocrine tumors. Hum Pathol 2002; 33:322-9.
11 Leotlela PD, Jauch A, Holtgreve Grez H, Thakker RV. Genetics of neuroendocrine and carcinoid tumours. Endocr Relat Cancer 2003; 10:437-50.
12 Pizzi S, D' Adda T, Azzoni C, Rindi G, Grigolato P, Pasquali C, Corleto VD, Delle Fave G, Bordi C. Malignancy-associated allelic losses on the X-chromosome in foregut but not in midgut endocrine tumours. J Pathol 2002; 196:401-7.
13 Pizzi S, Azzoni C, Bottarelli L, Campanini N, D' Adda T, Pasquali C, Rossi G, Rindi G, Bordi C. RASSF1A promoter methylation and 3p21.3 LOH label foregut, but not midgut and hindgut, malignant endocrine tumours. J Pathol in press.
14 Kytola S, Hoog A, Nord B, Cedermark B, Frisk T, Larsson C, Kjellman M.Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids. Am J Pathol 2001;158:1803-1808
15 Stancu M, Wu TT, Wallace C, Houlihan PS, Hamilton SR, Rashid A.: Genetic alterations in goblet cell carcinoids of the vermiform appendix and comparison with gastrointestinal carcinoid tumors.
Mod Pathol. 2003;16:1189-98
16 Tonnies H, Toliat MR, Ramel C, Pape UF, Neitzel H, Berger W, Wiedenmann B.: Analysis of sporadic neuroendocrine tumors of the enteropancreatic system by comparative genomic hybridisation. Gut 2001; 48:536–41
17 Lollgen RM, Hessman O, Szabo E, Westin G, Akerstrom G. Chromosome 18 deletions are common events in classical midgut carcinoid tumors. Int J Cancer 2001;92:812-815
18 Rindi G, Villanacci V, Ubiali A, Scarpa A. Endocrine tumors of the digestive tract and pancreas: histogenesis, diagnosis and molecular basis. Expert Rev Mol Diagn 2001;1:323-333
19 Toyota M, Issa JP. CpG island methylator phenotypes in aging and cancer. Semin Cancer Biol 1999; 9:349-357
20 Chan AO, Kim SG, Bedeir A, Issa JP, Hamilton SR, Rashid A: CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 2003;22: 924-34
21 Dammann R, Schagdarsurengin U, Liu L, Otto, N. Gimm, O. Dralle, H. Boehm, B. Pfeifer, G. P. Hoang Vu, C.Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 2003;22:3806-3812
22 House MG, Herman JG, Guo MZ, Hooker, C. M. Schulick, R. D. Lillemoe, K. D. Cameron, J. L. Hruban, R. H. Maitra, A. Yeo, C. J. Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann Surg 2003;238:423-431.
23 Bartsch DK, Kersting M, Wild A, Ramaswamy, A. Gerdes, B. Schuermann, M. Simon, B. Rothmund, M.: Low frequency of p16INK4a alterations in insulinomas. Digestion 2000; 62: 171-177
24 Serrano J, Goebel SU, Peghini PL, Lubensky IA, Gibril F, Jensen RT: Alterations in the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas. J Clin Endocrinol Metab 2000;85: 4146-56
25 Lubomierski, N., Kersting, M., Bert, T., Muench, K., Wulbrand, U., Schuermann, M., Bartsch, D., and Simon, B. Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors Cancer Res 2001; 61: 5905-5910
26 Maitra A, Hansel DE, Argani P, Ashfaq R, Rahman A, Naji A, Deng S, Geradts J, Hawthorne L, House MG, Yeo CJ. Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays. Clin Cancer Res 2003;9:5988-95
28 Albertson DG, Collins C, McCormick F, Gray JW: Chromosome aberrations in solid tumors. Nat Genet 2003;34: 369-76
27 Nacht M, Ferguson AT, Zhang W, Petroziello JM, Cook BP, Gao YH, Maguire S, Riley D, Coppola G, Landes GM, Madden SL, Sukumar S: Combining serial analysis of gene expression and array technologies to identify genes differentially expressed in breast cancer. Cancer Res 1999; 59: 5464-5470
29 Ciardiello F, Tortora G: Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 2003; 39: 1348-1354
30 Hopfner M, Sutter AP, Gerst B, Zeitz M, Scherubl H. A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839). Br J Cancer 2003; 89: 1766-75

Parole Chiave

TUMORI NEUROENDOCRINI; PROFILI DI ESPRESSIONE GENICA; MICROARRAY GENICI; ARRAY DI IBRIDIZZAZIONE GENOMICA COMPARATIVA; GENI ONCOSOPPRESSORI; METILAZIONE DEL PROMOTER; PROGNOSI; TERAPIA A BERSAGLIO